Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Conditions

• Staphylococcus Aureus Bacteremia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) — DRUG
  Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.
• Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) — DRUG
  Vancomycin or daptomycin, per discretion of the treating physician
• Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) — DRUG
  Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem
• Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) — DRUG
  Daptomycin plus ceftaroline

Study Details

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Key Dates

Start date

Feb 1, 2026

Status verified

Jan 2026

Primary completion

Jan 31, 2029

Completion

Jan 31, 2029

Study Design

Enrollment

2,096 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Experimental: Patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
  Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MSSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy
• Experimental: Patients with methicillin-resistant S. aureus bacteremia (MRSAB)
  Patients with methicillin-resistant S. aureus bacteremia (MRSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MRSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy

Primary Outcome Measure

Desirability of Outcome Ranking (DOOR) [ Time Frame: From enrollment to 30 days post enrollment ]

Central Contacts

• Brandon J Webb, MD
  801-507-7781
  [email protected]
• Whitney R Buckel, PharmD
  801-284-1046
  [email protected]

Locations (13)

Find similar trials in Brighton, CO

Related Studies

• Staphylococcus Aureus Network Adaptive Platform Trial
  PHASE4 · Recruiting · University of Melbourne · Houston, Texas
• Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
  PHASE4 · Enrolling By Invitation · West Virginia University · Morgantown, West Virginia